Prime Highlights
- Early trials indicate that Zorevunersen can significantly reduce seizures in children with Dravet syndrome, with some patients experiencing up to an 80% drop after three doses.
- Researchers also observed improvements in movement, communication, and daily life activities, suggesting broader developmental benefits beyond seizure control.
Key Facts
- The study involved 81 children aged 2–18and was conducted by University College London in collaboration with Great Ormond Street Hospital.
- Before treatment, participants averaged 17 seizures per month, which decreased by about 50% after a single 70 mg doseof Zorevunersen.
Background
Scientists reported promising early results from clinical trials of a new drug that could greatly help children with severe epilepsy. Researchers say the experimental medicine Zorevunersen has shown the potential to reduce seizures in children diagnosed with Dravet syndrome, a rare genetic condition that is often resistant to current treatments.
Researchers at University College London, working with Great Ormond Street Hospital, conducted an early-stage trial with 81 children aged two to 18. The results, published in The New England Journal of Medicine shows that participants generally tolerated the drug well and that generally safe.
Before the study began, the children experienced an average of 17 seizures each month. After receiving a 70 mg dose of Zorevunersen, seizure frequency dropped by about 50 percent on average. After three doses, the number of seizures fell by nearly 80 percent, according to the study findings.
Researchers also observed improvements in several areas of daily life. Many children improved their movement, communication, and daily life activities, suggesting that the treatment could support broader developmental progress beyond seizure control.
Helen Cross, lead author of the study and director of childhood epilepsy at UCL’s Institute of Child Health, said children with genetic epilepsies often face multiple seizures every week and require constant care. She added that if future trials confirm the results, the treatment could allow children with Dravet syndrome to live healthier and more independent lives.
Experts in epilepsy research have welcomed the findings. Jowinn Chew from London South Bank University described the results as an important step toward therapies that address the underlying genetic causes of epilepsy rather than only managing symptoms.
Researchers will now begin a Phase 3 clinical trial to study the treatment over a longer period and monitor possible long-term risks or rare side effects.
Scientists say the approach could create new treatment options for many other genetic epilepsies and give hope to families facing these serious brain disorders.
